Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits

Daniel Bertin (1) , Mélanie Serrero (2) , Jean Charles Grimaud (2) , Ariadne Desjeux (2) , Sophie Desplat-Jégo (3)

1 AMU - Aix Marseille Université
2 Hôpital Nord [CHU - APHM]
3 INP - Institut de neurophysiopathologie

Domaines: Biotechnologies

Daniel Bertin, Mélanie Serrero, Jean Charles Grimaud, Ariadne Desjeux, Sophie Desplat-Jégo. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits. Cytokine, 2020, 126, pp.154859. ⟨10.1016/j.cyto.2019.154859⟩. ⟨hal-02351814⟩